Evidence map›Paper›PMID 36959362›Full record

ArticleNature genetics2023

Thymidine nucleotide metabolism controls human telomere length.

William Mannherz, Suneet Agarwal

Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06817590 (Nucleoside Therapy in Patients With Telomere Biology Disorders), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06817590 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Nucleoside Therapy in Patients With Telomere Biology Disorders

TypeinterventionalSponsorSuneet AgarwalRan2025 to 2029Enrolled36ConditionsTelomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson SyndromeArmsdeoxycytidine, deoxythymidine
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 69 citations in OpenAlex.

  1. How telomere attrition protects against cancer.Nature reviews. Genetics · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. NADCommunications biology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

William MannherzDivision of Hematology/Oncology and Stem Cell Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4472-7394
Suneet AgarwalDivision of Hematology/Oncology and Stem Cell Program, Boston Children's Hospital, Boston, MA, USA. suneet.agarwal@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-4910-3118
Boston Children's Hospital · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Molecular, Cellular, & Developmental Dynamics PhD ProgramT32GM007226 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI VAN VACTOR, DAVID L. · 1985 to 2021
$14.4M
Translational Studies of Inherited Marrow Failure and Myelodysplastic SyndromesR24DK099808 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ABKOWITZ, JANIS L, EBERT, BENJAMIN LEVINE · 2013 to 2017
$8.2M
Regulation of the telomerase RNA component in hematopoiesisR01DK107716 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI SUNEET AGARWAL · 2016 to 2026
$5.0M
Novel small molecules to treat degenerative lung and blood diseasesR33HL154133 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI AGARWAL, SUNEET · 2020 to 2021
$1.2M
NHLBI NIH HHS R33 HL154133NIDDK NIH HHS R01 DK107716NIDDK NIH HHS R24 DK099808NIGMS NIH HHS T32 GM007226NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Telomere length in humans is associated with lifespan and severe diseases, yet the genetic determinants of telomere length remain incompletely defined. Here we performed genome-wide CRISPR-Cas9 functional telomere length screening and identified thymidine (dT) nucleotide metabolism as a limiting factor in human telomere maintenance. Targeted genetic disruption using CRISPR-Cas9 revealed multiple telomere length control points across the thymidine nucleotide metabolism pathway: decreasing dT nucleotide salvage via deletion of the gene encoding nuclear thymidine kinase (TK1) or de novo production by knockout of the thymidylate synthase gene (TYMS) decreased telomere length, whereas inactivation of the deoxynucleoside triphosphohydrolase-encoding gene SAMHD1 lengthened telomeres. Remarkably, supplementation with dT alone drove robust telomere elongation by telomerase in cells, and thymidine triphosphate stimulated telomerase activity in a substrate-independent manner in vitro. In induced pluripotent stem cells derived from patients with genetic telomere biology disorders, dT supplementation or inhibition of SAMHD1 promoted telomere restoration. Our results demonstrate a critical role of thymidine metabolism in controlling human telomerase and telomere length, which may be therapeutically actionable in patients with fatal degenerative diseases.

Indexed as

TelomeraseHumansNucleotidesSAM Domain and HD Domain-Containing Protein 1TelomereTelomere HomeostasisThymidineNucleotidesSAM Domain and HD Domain-Containing Protein 1TelomeraseThymidine

Identifiers

PMID36959362
PMCPMC11000509
OpenAlexW4360609967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.